Accessible Requires Authentication Published by De Gruyter November 1, 2007

Current state and future directions of neurochemical biomarkers for Alzheimer's disease

From the journal


In this comprehensive review, we summarize the current state-of-the-art of neurochemical biomarkers for Alzheimer's disease. Predominantly, these biomarkers comprise cerebrospinal fluid biomarkers directly related to the pathophysiology of this disorder (such as amyloid β protein, tau protein). We particularly pay attention to the innovations in this area that have been made in technological aspects during the past 5 years (e.g., multiplex analysis of biomarkers, proteomics), to the discovery of novel, potential biomarkers (e.g., amyloid β oligomers, isoprostanes), and to the extension of this research towards identification of biomarkers in plasma.

Clin Chem Lab Med 2007;45:1421–34.

Corresponding author: Dr. M.M. Verbeek, PhD, MSc, Department of Neurology, 830 LKN, Radboud University Nijmegen Medical Center, P.O. Box 9101, 6500 Nijmegen, The Netherlands Phone: +31-24-3614567, Fax: +31-24-3668754,

Received: 2007-6-7
Accepted: 2007-8-28
Published Online: 2007-11-01
Published in Print: 2007-11-01

©2007 by Walter de Gruyter Berlin New York